Prognostic effect of DNA aneuploidy from bladder washings in superficial bladder cancer

Cancer Epidemiology Biomarkers and Prevention

Volumn 16, Issue 5, 2007, Pages 979-983

  Puntoni, Matteo ^a,b   Zanardi, Silvia ^a   Branchi, Daniela ^a   Bruno, Silvia ^b   Curotto, Antonio ^b   Varaldo, Marco ^c   Bruzzi, Paolo ^d   Decensi, Andrea ^a,e  

^a GALLIERA HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c VILLA SCASSI HOSPITAL   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; FENRETINIDE;

ADULT; AGED; ANEUPLOIDY; ARTICLE; BLADDER CANCER; BLADDER IRRIGATION; CANCER GROWTH; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; SUPERFICIAL CANCER;

ADULT; AGED; AGED, 80 AND OVER; ANEUPLOIDY; ANTICARCINOGENIC AGENTS; COHORT STUDIES; DISEASE PROGRESSION; DNA, NEOPLASM; FEMALE; FENRETINIDE; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL; URINARY BLADDER; URINARY BLADDER NEOPLASMS;

EID: 34250323724     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-06-0538     Document Type: Article

References (39)

1. Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97:1407-27.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2006. CA Cancer J Clin 2006;56:106-130.
3. 1/CIS) cell carcinoma of the bladder. BJU Int 2004;94:18-21.
4. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: epidemiology, staging and grading, and diagnosis. Urology 2005;66:4-34.
5. Ali-El-Dein B, Sarhan O, Hinev A, Ibrahiem el-HI, Nabeeh A, Ghoneim MA. Superficial bladder tumours: analysis of prognostic factors and construction of a predictive index. BJU Int 2003;92:393-9.
6. Sengupta S, Blute ML. The management of superficial transitional cell carcinoma of the bladder. Urology 2006;67:48-54.
7. a (noninvasive) urothelial carcinoma of the bladder. Urology 2005;66:75-89.
8. 1 tumors of the bladder: International Consensus Panel. Urology 2005;66:108-25.
9. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 2002;8:314-46.
10. Stein JP, Grossfeld GD, Ginsberg DA, et al. Prognostic markers in bladder cancer: a contemporary review of the literature. J Urol 1998;160:645-59.
11. Habuchi T, Marberger M, Droller MJ, et al. Prognostic markers for bladder cancer: International Consensus Panel on bladder tumor markers. Urology 2005;66:64-74.
12. Decensi A, Bruno S, Costantini M, et al. Phase IIa study of fenretinide in superficial bladder cancer, using DNA flow cytometry as an intermediate end point. J Natl Cancer Inst 1994;86:138-40.
13. Schatzkin A, Freedman LS, Dorgan J, McShane LM, Schiffman MH, Dawsey SM. Surrogate end points in cancer research: a critique. Cancer Epidemiol Biomark Prev 1996;5:947-953.
14. Kelloff GJ, Hawk ET, Karp JE, et al. Progress in clinical chemoprevention. Semin Oncol 1997;24:241-252.
15. Wheeless LL, Badalament RA, de Vere White RW, Fradet Y, Tribukait B. Consensus review of the clinical utility of DNA cytometry in bladder cancer. Report of the DNA Cytometry Consensus Conference. Cytometry 1993;14:478-81.
16. Decensi A, Torrisi R, Bruno S, et al. Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate end point. Cancer Epidemiol Biomarkers Prev 2000;9:1071-8.
17. i urothelial cell cancer predict recurrence and stage progression more accurately than stage, grade, or treatment modality. Urology 2003;61:1266-72.
18. Vindelov LL, Christensen IJ, Engelholm SA, et al. Prognostic significance of DNA content in bladder cancer based on flow cytometric analysis of 249 transitional cell carcinomas. Cytometry 1995;22:93-102.
19. Lipponen PK, Nordling S, Eskelinen MJ, Jauhiainen K, Terho R, Harju E. Flow cytometry in comparison with mitotic index in predicting disease outcome in transitional-cell bladder cancer. Int J Cancer 1993;53:42-7.
20. Tachibana M, Miyakawa A, Miyakawa M, et al. Prognostic significance of flow cytometric deoxyribonucleic acid analysis for patients with superficial bladder cancers: a long-term follow-up study. Cancer Detect Prev 1999;23:155-62.
21. Decensi A, Torrisi R, Bruno S. Randomized trial of fenretinide in superficial bladder cancer using DNA flow cytometry as an intermediate endpoint. Proc Am Soc Clin Oncol Annu Meet 1997;16:541.
22. Bruno S, Torrisi R, Costantini M, et al. Assessment of DNA flow cytometry as a surrogate end point biomarker in a bladder cancer chemoprevention trial. J Cell Biochem 1999;76:311-21.
23. Decensi A, Fontana V, Bruno S, Gustavino C, Gatteschi B, Costa A. Effect of tamoxifen on endometrial proliferation. J Clin Oncol 1996;14:434-440.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
25. Cox DR. Regression models and life tables with discussion. J Roy Stat Soc B 1972;34:187-192.
26. Veglia F, Matullo G, Vineis P. Bulky DNA adducts and risk of cancer: a meta-analysis. Cancer Epidemiol Biomarkers Prev 2003;12:157-60.
27. Hultin TA, May CM, Moon RC. N-(4-Hydroxyphenyl)-all-trans retinamide pharmacokinetics in female rats and mice. Drug Metab Dispos 1986;14:714-7.
28. Moon RC, McCormick DL, Becci PJ, et al. Influence of 15 retinoic acid amides on urinary bladder carcinogenesis in the mouse. Carcinogenesis 1982;3:1469-1472.
29. Hicks RM, Turton JA, Chowaniec J, et al. Modulation of carcinogenesis in the urinary bladder by retinoids. Ciba Found Symp 1985;113:168-190.
30. Waliszewski P, Waliszewska M, Gordon N, et al. Retinoid signaling in immortalized and carcinoma-derived human uroepithelial cells. Mol Cell Endocrinol 1999;148:55-65.
31. Sabichi AL, Seth PL, Atkinson EN, et al. Phase III bladder cancer chemoprevention trial with fenretinide. Proceedings of the Fifth Annual AACR International conference on Frontiers in Cancer Prevention Research, Nov 12-15 2006;abstract #A148.
32. Albanes D, Heinonen OP, Taylor PR, et al. α-Tocopherol and β-carotene supplements and lung cancer incidence in the α-tocopherol, β-carotene cancer prevention study: effects of base-line characteristics and study compliance. J Natl Cancer Inst 1996;88:1560-70.
33. Omenn GS, Goodman GE, Thornquist MD, et al. Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst 1996;88:1550-9.
34. Liu C, Russell RM, Wang XD. Exposing ferrets to cigarette smoke and a pharmacological dose of β-carotene supplementation enhance in vitro retinoic acid catabolism in lungs via induction of cytochrome P450 enzymes. J Nutr 2003;133:173-9.
35. Liu C, Wang XD, Bronson RT, Smith DE, Krinsky NI, Russell RM. Effects of physiological versus pharmacological β-carotene supplementation on cell proliferation and histopathological changes in the lungs of cigarette smoke-exposed ferrets. Carcinogenesis 2000;21:2245-53.
36. Lotan R. Retinoids and apoptosis: implications for cancer chemoprevention and therapy. J Natl Cancer Inst 1995;87:1655-7.
37. Dmitrovsky E. Fenretinide activates a distinct apoptotic pathway. J Natl Cancer Inst 2004;96:1264-5.
38. Oridate N, Suzuki S, Higuchi M, Mitchell MF, Hong WK, Lotan R. Involvement of reactive oxygen species in N-(4-hydroxyphenyl) retinamide-induced apoptosis in cervical carcinoma cells. J Natl Cancer Inst 1997;89:1191-8.
39. Lovat PE, Di Sano F, Corazzari M, et al. Gangliosides link the acidic sphingomyelinase-mediated induction of ceramide to 12-lipoxygenase-dependent apoptosis of neuroblastoma in response to fenretinide. J Natl Cancer Inst 2004;96:1288-99.